02/01/2012
REDWOOD CITY, California—Proteus Biomedical, a specialist in digital health, said the United States Patent Office will award U.S. Patent Number 8,114,021 to Proteus. The patent, entitled “Body Associated Receiver and Method,” is directed to the Proteus wearable and ingestible sensor
technologies and related sensor devices used to create digital…
01/31/2012
BOGOTA, Colombia—With demand for health care rising across Latin America, Advent International and Essex Woodlands Health Ventures have acquired a controlling stake in Grupo Farmaceutico Biotoscana S.A. in a deal that will fuel the Colombian drug-maker’s growth into Mexico and Brazil.
01/23/2012
Taking advantage of a modest stock bump following its presentation at the J.P. Morgan Healthcare Conference earlier this month, Ziopharm Oncology Inc. priced a $50.2 million public offering to support ongoing work with late-stage programs, including palifosfamide and a DNA therapeutic gained via last year’s partnership with Intrexon Corp.
01/05/2012
SOUTH SAN FRANCISCO, California—Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today
announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences. PF-05280602 has been engineered…
01/04/2012
HOUSTON, Texas – Essex Woodlands (www.ewhv.com), a global healthcare growth equity and venture capital firm, announced today a strategic partnership with Smith & Nephew (http://global.smith-nephew.com/master/6600.html), the largest UK-based medical device company, to fund the spinout of Smith & Nephew’s Biologics and Clinical Therapies division and develop a leading global orthopedic…